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1204it greatly increases the risk of incorrectly concluding
that no interaction effect exists when in reality it
does (2). When we calculated the power of detecting
such interaction in the DAPT study as suggested by
Brookes et al. (3) this was roughly as low as 29%.
Misinterpreting such a ﬁnding, which has indeed
a plausible biological explanation (i.e., patients
without prior myocardial infarction are at lower risk
for ischemic recurrences, show lower platelet reac-
tivity, and have potentially higher rate of bleeding
when treated with prolonged antithrombotic therapy)
(4), may expose a large number of patients to un-
necessary bleeding events, which do carry prognostic
implications and may ultimately worsen outcomes.
Deﬁning which subgroups of patients derive a
beneﬁt and which harm from an extended DAPT
regimen is urgent, given the level of uncertainty
clearly voiced by the medical community (5).Francesco Costa, MD
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reduction in stent thrombosis and myocardialinfarction (MI) and an increase in bleeding with
continued thienopyridine therapy beyond 12 months
after coronary stent treatment (1). In subgroup
analysis (2), continued thienopyridine therapy pro-
vided consistent reductions in ischemic endpoints
irrespective of clinical presentation (MI Group, haz-
ard ratio: 0.27 for stent thrombosis and 0.42 for MI;
No MI Group, hazard ratio: 0.30 for stent thrombosis
and 0.60 for MI). Global Utilization of Streptokinase
moderate or severe bleeding was increased with
continued thienopyridine in both groups (hazard
ratio: 2.38 and 1.53, respectively). The conclusions,
that extended dual antiplatelet therapy reduced
stent thrombosis and MI but increased bleeding
irrespective of clinical presentation, are objectively
supported by the results of this substudy.
The DAPT study was not powered to evaluate the
effect of continued thienopyridine on mortality. We
nevertheless published the MI subgroup data for
mortality to fully acknowledge the importance of this
outcome. However, emphasis on a nonsigniﬁcant,
albeit underpowered, interaction for an individual
component endpoint in a non-pre–speciﬁed analysis
could lead to an erroneous conclusion because of
either type I or type II error. Thus, the ﬁnding,
although notable, should be considered hypothesis-
generating, not conclusive.
Although bleeding is certainly a risk of continued
dual antiplatelet therapy, the difference in mortality
seen in the DAPT study was not, in fact, accounted
for by a difference in antecedent bleeding (1). In
addition, a secondary blinded adjudication using a
sensitive deﬁnition for bleeding-related death did
not support bleeding as the primary reason for the
difference in mortality. Finally, a large comprehen-
sive meta-analysis found no relationship between
extended duration dual antiplatelet therapy and
mortality (3). Subsequent meta-analyses focused only
on drug-eluting stent populations have been driven
by the DAPT study results, and have selectively
excluded studies with populations for whom the
relationship between antiplatelet therapy and mor-
tality, as mediated by bleeding, are applicable (4).
Mortality is undoubtedly a critically important
endpoint in the evaluation of the risks and beneﬁts of
any therapy. We believe that the mortality differ-
ences observed in the DAPT study require careful
attention because of the potential for harm to the
many individuals exposed to this treatment. Howev-
er, the expedient explanation that bleeding explains
the observed mortality differences is not currently
supported by trial data. A disciplined interpretation
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mature conclusions that, although well intentioned,
may in fact jeopardize patient safety.Robert W. Yeh, MD, MSc
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